MedTrace Logo

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

NCT03022396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2017-08-21

Study results available
· View outcomes & findings →

Summary

This study will investigate response to influenza vaccines in monozygotic and dizygotic twins of different ages.

Conditions

Interventions

BIOLOGICAL

High Dose Fluzone® (intramuscular)

Licensed seasonal High dose trivalent inactivated influenza

BIOLOGICAL

Fluzone® (intramuscular)

Licensed seasonal trivalent inactivated influenza

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Mark Davis, PhD · Stanford University

  • Garry Nolan, PhD · Stanford University

  • Ann Arvin, MD · Stanford University

  • Stephen Quake, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03022396 on ClinicalTrials.gov